For research use only. Not for therapeutic Use.
Cinrebafusp alfa（Cat No.:I042111）is an investigational bispecific fusion protein being developed for the treatment of cancer. It combines two mechanisms of action: one arm targets and blocks the immune checkpoint protein PD-L1, while the other activates CD40, a receptor involved in immune system activation. This dual approach aims to both enhance anti-tumor immunity and reduce tumor immune evasion. Cinrebafusp alfa is being evaluated in clinical trials for various cancers, including solid tumors, to assess its safety, efficacy, and potential to improve treatment outcomes when used alone or in combination with other therapies.
| Catalog Number | I042111 |
| CAS Number | 2218515-90-1 |
| Purity | ≥95% |
